Open AccessBiological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model
Author(s) -
Joseph A. Davis,
Pucha S Kumar,
Sant P. Singh,
A Surender,
Suvra Roy,
Vivek Khanna,
Sachin Sethi,
Chanchan Pal,
Lalima Sharma,
Biju Benjamin,
Shivani Mittra,
Jitendra A. Sattigeri,
Vinay S. Bansal
Publication year - 2012
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.103298
Subject(s) - sitagliptin , dipeptidyl peptidase , incretin , potency , chemistry , in vivo , pharmacology , type 2 diabetes , proteases , vildagliptin , endocrinology , medicine , dipeptidyl peptidase 4 , enzyme , diabetes mellitus , in vitro , biochemistry , biology , microbiology and biotechnology
Dipeptidyl peptidase IV (DPP-IV) inhibition to modulate the incretin effect is a proven strategy to treat type 2 diabetes mellitus. The present study describes the pharmacological profile of a novel DPP-IV inhibitor RBx-0128, as an antidiabetic agent.